Acquisition- Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Oct. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Asset Acquisition [Line Items]
Asset acquisition, upfront payment		$ 31,346	$ 0	$ 0
Acquired IPR&D expense		$ 87,184	$ 0	$ 0
ImmPACT Bio USA Inc.
Asset Acquisition [Line Items]
Asset acquisition, upfront payment	$ 30,000
Cash acquired from acquisition	$ 11,900
Stock issued during period, shares, acquisitions (in shares)	37,500,000
Asset acquisition, contingent consideration arrangements, entity shares issuable (in shares)	12,500,000
Asset acquisition, contingent consideration payable, shares held (in shares)		12,500,000
Asset acquisition, equity consideration, price per share (in dollars per share)	$ 0.9603
Acquired IPR&D expense		$ 87,200